[Skip to Navigation]
[Skip to Navigation Landing]
May 16, 2019

Association of Choroidal Effusion and Infusion of Daratumumab

Author Affiliations
  • 1Department of Ophthalmology, Rigshospitalet Glostrup, University Hospital Copenhagen, Copenhagen, Denmark
  • 2Department of Hematology, Rigshospitalet, University Hospital Copenhagen, Copenhagen, Denmark
JAMA Ophthalmol. 2019;137(7):853-854. doi:10.1001/jamaophthalmol.2019.1427

Daratumumab is the first in-class monoclonal anti-CD38 immunoglobulin G1 antibody with proven antimyeloma activity in both monotherapy and in combination with drugs such as lenalidomide and bortezomib.1 It has a favorable safety profile with typical adverse events such as upper respiratory tract symptoms at first infusion and later immunosuppressive effects.2